StockNews.AI
LXRX
StockNews.AI
168 days

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

1. Lexicon will release Q4 and full year 2024 results on March 6, 2025. 2. A conference call will discuss financial results and business updates. 3. Lexicon focuses on innovative drugs for various diseases utilizing genomics. 4. Multiple drugs are in clinical and preclinical development phases. 5. Results will potentially indicate financial health and future prospects.

4m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results may exceed expectations, reflecting positive growth and investor confidence.

How important is it?

Financial results can directly influence stock performance; upcoming data will guide investor sentiment.

Why Short Term?

Immediate market reactions are expected post-announcement of financial results.

Related Companies

VRTXAMGNREGN
March 04, 2025 16:15 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, March 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its fourth quarter and full year 2024 financial results on Thursday, March 6, 2025 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.  About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.  For Investor and Media Inquiries: Lisa DeFrancesco  Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com 

Related News